Bone Reports · 2015 · 20 citations · 28 references
MedicinePharmacologyPharmacotherapyBioavailabilityBone MetabolismPharmacodynamicsBone BiomechanicsBone HealthBone HistomorphometryBone MechanicsBone PhysiologyBone ResorptionBone Mass AcquisitionBone Mass GainBone Mineral LossBone Volume FractionControl Group DesignDrug Effects On Bone DensityMatched Control GroupTrabecular Bone Loss
The aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA) on bone mass, femoral microstructure, femoral biomechanical properties, and bone remodeling in healthy adult male rats. Forty-eight 5-month-old male Wistar rats were used. CsA (2 mg/kg/day), FK-506 (3 mg/kg/day), RAPA (1.25 mg/kg/day), or water (0.5 ml/rat/day, control group) were administered orally for 3 months. After sacrifice, mean values of immunosuppressants in blood were: CsA (670.4 ng/ml), FK-506 (19.2 ng/ml), and RAPA (4.8 ng/ml). Levels of biochemical parameters were normal in all groups. Femoral BMD was decreased in FK-506 and RAPA groups and lumbar BMD in FK-506 group. Trabecular volume fraction (BV/TV) decreased only in FK-506 group. RAPA and CsA affected femoral cortical structure, but FK-506 did not. FK-506 produced an increase in bone remodeling, and CsA a decrease. FK-506 group showed a decrease in biomechanical parameters relative to all groups. RAPA group showed a decrease in ultimate stress vs control group, and CsA group presented an increase in biomechanical parameters versus control group. We found that administration of both RAPA and FK-506 as monotherapy for healthy rats produced osteopenia. CsA treatment only produces slight damages in the cortical zone of the femur.
28
Osteoporosis after cardiac transplantation
Elizabeth Shane, Maria del Carmen Rivas, Shonni J. Silverberg et al. · The American Journal of Medicine · 1993 · 195 citations
Medicine, Cardiology, Surgery +7